Drug intelligence / Profile preview

BGB-A3055

Development stage: Discontinued
Lead developer: BeiGene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BGB-A3055 is an investigational, humanized, afucosylated IgG1 monoclonal antibody designed to target C-C motif chemokine receptor 8 (CCR8). CCR8 is highly and selectively expressed on immunosuppressive regulatory T cells (Tregs) within the tumor microenvironment. By binding to CCR8, BGB-A3055 blocks its interaction with the chemokine ligand CCL1 and induces potent antibody-dependent cellular cytotoxicity (ADCC) to selectively deplete intratumoral Tregs while sparing peripheral Tregs. Developed by BeOne Medicines (formerly BeiGene), BGB-A3055 has been evaluated in Phase 1 clinical trials as a monotherapy and in combination with the anti-PD-1 antibody tislelizumab for the treatment of advanced or metastatic solid tumors.

Targets

CCL1CCR8FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)

Beyond the preview

Go deeper on BGB-A3055.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BGB-A3055.